The post Dogecoin, Shiba Inu slid deeper as on-chain activity spike appeared on BitcoinEthereumNews.com. Dogecoin and Shiba Inu slid deeper into selloff territoryThe post Dogecoin, Shiba Inu slid deeper as on-chain activity spike appeared on BitcoinEthereumNews.com. Dogecoin and Shiba Inu slid deeper into selloff territory

Dogecoin, Shiba Inu slid deeper as on-chain activity spike

Dogecoin and Shiba Inu slid deeper into selloff territory even as on-chain activity spiked, underscoring a growing disconnect between network usage and price action across the meme-coin sector.

Summary

  • Despite a 36% surge in Dogecoin active addresses, prices fell 3%, with Shiba Inu also losing 2%.
  • Increased network activity is driven more by distribution than accumulation, signaling vulnerability to further declines.
  • Trading at $0.00000641, SHIB is down 92% from its 2021 peak, facing weak transaction volumes and uncertain future utility.

Dogecoin (DOGE) active addresses jumped 36% over the past week to more than 71,400, signaling renewed participation on the network.

But the surge failed to support prices, with DOGE falling 3% to about $0.102 and Shiba Inu dropping 2% to roughly $0.0000066.

Heavy net outflows, weakening technical structures, and broken support levels suggest both tokens remain vulnerable to further downside, as increased activity appears driven more by distribution than accumulation.

Dogecoin, originally created as a joke in 2013, briefly soared to a $90 billion market cap in 2021 but has since lost over 90% of its value.

Source: CoinGecko

Despite a rally in late 2024, the meme coin remains down 62% in 2025 and lacks a real use case like Bitcoin or Ethereum.

Its speculative nature and endless supply—leading to constant dilution—make it vulnerable to further declines. With no fundamental catalysts in sight, a 50% drop in 2026, potentially returning Dogecoin to its 2022 low of $0.05, seems likely.

Shiba Inu is the pits

Shiba Inu (SHIB) has been volatile after recently hitting a monthly low of $0.0000065 on February 1, following a high of $0.0000097 on January 6.

These price swings reflect SHIB’s sensitivity to sentiment and liquidity.

Source: CoinGecko

Shiba Inu is currently trading at $0.00000641, a 92% drop from its October 2021 all-time high. The token is below key moving averages, and while the RSI shows oversold conditions, no reversal has occurred. SHIB is testing critical support at $0.00000638, and a breakdown below this level could push it to $0.0000055.

The Shiba Inu ecosystem is facing challenges, including weak daily transaction volume and a lack of sustained utility, despite its integration of Fully Homomorphic Encryption (FHE) in Q2 2026, which could boost privacy and security. The launch of a crypto ETF by T. Rowe Price could also attract regulated capital, but approval odds are low.

According to one report, Shiba Inu’s price could range between $0.000015-$0.000025 by 2027 if privacy upgrades succeed and the ETF is approved, with conservative estimates placing it between $0.000010–$0.000015.

Key resistance levels are $0.00000732, $0.0000078, and $0.00000851. Monitoring Shibarium transaction volumes and burn rates, along with Bitcoin’s performance, will be key for investors tracking SHIB’s potential recovery.

Source: https://crypto.news/dogecoin-shiba-inu-slid-deeper-on-chain-activity-spike/

Market Opportunity
SHIBAINU Logo
SHIBAINU Price(SHIB)
$0.000005971
$0.000005971$0.000005971
-1.98%
USD
SHIBAINU (SHIB) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26